(Total Views: 234)
Posted On: 06/08/2017 11:33:39 AM
Post# of 72447
Kevetrin: discussed with big pharma. They need to see how Kevetrin modulates the tumor (biopsy); 2) with Kevetrin's short half-life they want to see non-intravenous form of dosing.
Trying to establish mechanism of action. Measure p53 activity, RNA sequencing, safety and efficacy. Independent researchers in Italy have shared info on mechanism of action and will presenting in Madrid at end of month.
Excited about work thus far on oral formulation. Could increase therapeutic effect because of more frequent dosing. 79% bioavailability. Oral and intraperitoneal administration is similar in animals. Need to perform Phase 1 in HEALTHY adults so can go to FDA for trial approval.
Trying to establish mechanism of action. Measure p53 activity, RNA sequencing, safety and efficacy. Independent researchers in Italy have shared info on mechanism of action and will presenting in Madrid at end of month.
Excited about work thus far on oral formulation. Could increase therapeutic effect because of more frequent dosing. 79% bioavailability. Oral and intraperitoneal administration is similar in animals. Need to perform Phase 1 in HEALTHY adults so can go to FDA for trial approval.
(3)
(0)
